Navigation Links
Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019
Date:7/18/2014

(PRWEB) July 18, 2014

Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends wrong signals. Seizures could differ from primary generalized seizures to partial seizures depending upon the cause of the epilepsy. Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages. For the treatment of epilepsy, doctors prescribe antiepileptic medicines (AEDs) and the preference for the drug depends on the type of seizures to be treated, age of the patient, part of the brain involved and seriousness of the seizures. On the basis of the available AEDs, epilepsy therapeutics market is segmented into two major categories namely first generation AEDs and second generation AEDs. First generation AEDs consist of following drugs:

Get report sample PDF copy from here: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2448.

  • Carbamazepine (Carbatrol)
  • Valproate (Depakote)
  • Oxycarbazepine ((Trileptal)
  • Phenytoin (Dilantin, Phenytek)
  • Ethosuximide (Zarontin)
  • Phenobarbital (Luminal)
  • Primidone (Mysoline)
  • Topiramate (Topamax)

Second generation AEDs consist of medicines with different mechanism of action than the first generation drugs. This segment of epilepsy therapeutics market consists of following drugs:

  • Pregabalin (Lyrica)
  • Lamotrigine (Lamictal)
  • Levetiracetam (Keppra)
  • Zonisamide (Zonegran)
  • Lacosamide (Vimpat)
  • Eslicarbazepine acetate (Aptiom/Zebinix)
  • Perampanel (Fycompa)
  • Ezogabine/retigabine (Trobalt/Potiga)
  • Rufinamide (Banzel/Inovelon)

Early buyers will receive 10% customization on this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2448.

First generation AEDs majorly carbamazepine, valproate, phenytoin and oxycarbazepine dominates the epilepsy therapeutics market. However, second generation AEDs such as levetiracetam, zonisamide and lacosamide are slowly overtaking the epilepsy therapeutics market due to its improved efficacy and tolerability. Additionally, large number of research and development activities, are going on all over the world for the development of antiepileptic medicines with diverse mechanism actions. As for instance two major players of epilepsy therapeutics market namely UCB Pharma Ltd. and Marinus Pharmaceuticals, Inc. has developed brivaracetam and ganaxolone respectively, for treating epilepsy. Both of these drugs are currently under clinical trials and it is expected that these drugs will prove beneficial for epilepsy therapeutics market.

North America leads the epilepsy therapeutics market followed by Europe majorly due to the extensive research and development activities and availability of second generation drugs. Three new AEDs have been approved in U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate and it expected that brivaracetam will be approved soon. Ezogabine/retigabine and perampanel among these have novel mechanism of action and thus it is capturing good amount of market share in U.S. Continuous increase in uptake of second generation AEDs is also driving the epilepsy therapeutics market in North America and Europe. Asia-Pacific is also increasing at faster pace for epilepsy therapeutics market. High prevalence of epilepsy in India and China, increased penetration due to better market access options in China and expected approval of drugs with novel mechanisms are some of the factors responsible for expanding the epilepsy therapeutics market in the Asia-Pacific region. Conversely, the prescribing pattern of drugs that give preference to first generation AEDs over second generation AEDs is restraining the epilepsy therapeutics market in this region.

Contact:
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com
More reports on: https://www.linkedin.com/today/author/73190868.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12029023.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Canada should play a role in addressing the global cancer epidemic
3. Global cardiology leaders meet in Dubai
4. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
5. International breast health global summit will focus on supportive care and quality of life
6. Scientists rewrite rulebook on breast cancer in landmark global study
7. Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology
8. Centre for Global Non-Communicable Diseases launched to tackle killer diseases
9. UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity
10. New study identifies how information technology is used to solve global health challenges
11. New global report says US lags behind 130 other nations in preterm birth rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Seattle, WA (PRWEB) , ... February 05, 2016 ... ... consulting firm, ranked #3 in the 2015 Best in KLAS: Software & Services ... The annual Best in KLAS report independently ranks vendor performance by healthcare ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... 2016  The Senior Care Pharmacy Coalition (SCPC) ... Chairman Jason Chaffetz (R-UT) and Ranking ... hearing , "Developments in the Prescription Drug Market," ... questions about abusive pharmacy benefit manager (PBM) pricing ... Ranking Member Elijah Cummings (D-MD) are diligent, serious ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
Breaking Medicine Technology: